1448670-00-5

Upstream product

• 1448669-98-4 ethyl 2-(4-(4-formylphenyl)cyclohexyl)acetate 
• 1448669-99-5 ethyl 2-(4-(4-(5-nitro-1H-benzo[d]imidazol-2-yl)phenyl)cyclohexyl)acetate 
• 411238-92-1 ethyl 2-(4-phenylcyclohexyl)acetate 
• 115880-04-1 ethyl 2-(4-phenylcyclohexylidene)acetate 
• 4894-75-1 1-phenyl-4-cyclohexanone 

Downstream Products

• 1448670-02-7 ethyl 2-(4-(4-(5-(2-phenyl-5-(trifluoromethyl)oxazole-4-carboxamido)-1H-benzo[d]imidazol-2-yl)phenyl)cyclohexyl)acetate 
• 1448669-87-1 C₂₆H₂₅N₃O₄ 
• 1448669-88-2 C₃₄H₃₁N₃O₃ 
• 1448669-89-3 C₃₀H₂₇N₃O₃S 
• 1448669-90-6 C₃₀H₂₇N₃O₄ 
• 1448669-91-7 C₃₀H₂₇N₅O₄ 
• 1448669-93-9 C₃₂H₂₈F₃N₅O₃ 
• 1448669-94-0 C₃₂H₃₀N₄O₄ 
• 1448669-95-1 C₂₇H₂₅F₃N₄O₄ 
• 1448669-96-2 C₃₂H₂₆ClF₃N₄O₄ 
• 1448669-97-3 C₃₃H₂₆F₆N₄O₄ 
• 1448669-82-6 C₂₈H₂₈N₄O₃ 
• 1448669-83-7 C₂₂H₂₄N₄O₂S 
• 1448669-84-8 C₂₈H₂₈N₄O₂S 

Relevant academic research and scientific papers

Synthesis and biological evaluation of aminobenzimidazole derivatives with a phenylcyclohexyl acetic acid group as anti-obesity and anti-diabetic agents

A series of benzimidazole derivatives with a phenylcyclohexyl acetic acid group as DGAT-1 inhibitors was developed. Among the benzimidazole series, compound 5k showed submicromolar in vitro activity toward human and mouse DGAT-1, good selectivity toward D